The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Study of Paclitaxel Micelles for Injection in Chinese Patients With Advanced Solid Tumors.
Official Title: A Phase I Study of Dose Escalation and Dose Expansion To Evaluate the SafetyăTolerabilityăPharmacokinetics and Efficacy of Paclitaxel Micelles for Injection in Chinese Patients With Advanced Solid Tumor.
Study ID: NCT04778839
Brief Summary: A Phase I Study of Dose Escalation and Dose Expansion To Evaluate the SafetyăTolerabilityăPharmacokinetics and Preliminary Efficacy of Paclitaxel Micelles for Injection in Chinese Patients With Advanced Solid Tumor.
Detailed Description: The study will be conducted in two parts. The first part is dose escalation and the second part is dose Expansion.During the course of dose escalation, 18-27 subjects will be enrolled to assess the safetyătolerabilityăpharmacokineticsăpreliminary efficacy ,and determine the dose-limiting toxicity (DLT) and maximum tolerated dose(MTD) of Paclitaxel Micelles for Injection, and explore phase II clinical dosages. The second part will be adjusted according to the result of the first part. It will be divided into 4 groups, including advanced breast cancer group, ovarian cancer group, non-small cell lung cancer group and gastric cancer group, with 20 subjects in each group, to further evaluate the safety, tolerance, PK and anti-tumor activity of paclitaxel micelle.
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
The First Affiliated Hospital,ZheJiang Univercity, Hanzhou, Zhejiang, China
Name: jian liu, master
Affiliation: The First Affiliated Hospital,ZheJiang Univercity
Role: PRINCIPAL_INVESTIGATOR
Name: xiaochen zhang, docter
Affiliation: The First Affiliated Hospital,ZheJiang Univercity
Role: PRINCIPAL_INVESTIGATOR